About 200 reports

  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H2 2017
  • PTX-15 - DRUG PROFILE

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Pharmaceutical
  • Targeted Therapy
  • Transplantation
  • Vaccine
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF HEART TRANSPLANT REJECTION TO IMMUNOLOGY CLINICAL TRIALS
  • PROPORTION OF HEART TRANSPLANT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Clinical Trial
  • Heart Transplant
  • Immunology
  • Targeted Therapy
  • Vaccine

WE ARE FULFILLING OUR PROMISE TO MAKE SEQUENCING BASED INFORMATION AVAILABLE TO THE TRANSPLANT CLINIC, NOW ALSO FOR HEART TRANSPLANT PATIENTS. "

  • Orthopedics
  • Patient Monitoring
  • Vaccine
  • Canada
  • North America

Food and Drug Administration (FDA), World Health Organization (WHO), GLOBOCAN, and various organ transplant registries.

  • Medical Device
  • Orthopedics
  • North America
  • United States
  • Zimmer Biomet Holdings, Inc.

Liver transplant replaces an injured or diseased liver with a healthy one.

  • General Medicine And Specialty Medicine
  • Liver Transplant
  • Targeted Therapy
  • Transplantation
  • Vaccine

ANNOUNCED IT HAS RECEIVED FDA APPROVAL FOR ITS HEARTWARE HVAD SYSTEM AS A DESTINATION THERAPY FOR PATIENTS WITH ADVANCED HEART FAILURE WHO ARE NOT CANDIDATES FOR HEART TRANSPLANTS.

  • Patient Monitoring
  • Vaccine
  • Forecast
  • Market Size
  • Abbott
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Immunology
  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Vaccine

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World

Almost all of these artificial hearts are used as a bridge to human heart transplantation.

  • Cardiac Management
  • Cardiovascular Devices
  • Medical Device
  • Patient Monitoring
  • Vaccine

KANTER, M. D., PROFESSOR OF SURGERY AND DIRECTOR OF THE HEART TRANSPLANT PROGRAM AT CHILDREN' S HEALTHCARE IN ATLANTA AT EMORY UNIVERSITY SCHOOL OF MEDICINE, WHICH WAS THE TOP ENROLLING SITE FOR THE TRIAL THAT LED TO APPROVAL OF THIS NEW TREATMENT OPTION.

  • Immunology
  • Patient Monitoring
  • Vaccine
  • China
  • East Asia
  • CAREDX ENTERS INTO LICENSING AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA

ONE UNIT REFERS TO ONE PROBE.

  • Immunology
  • Patient Monitoring
  • Vaccine
  • Australasia
  • Australia

Global Number Of Heart Transplant Procedures Performed, 2016, By Country; ##. ##.

  • Cardiovascular Devices
  • Health Services
  • Patient Monitoring
  • World
  • Market Size

WE STARTED WITH EYECARE - AND TODAY WE ARE EXPANDING INTO CARDIAC CARE.

  • Immunology
  • Patient Monitoring
  • Targeted Therapy
  • India
  • South Asia
  • CAREDX ENTERS INTO LICENSING AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA

CARDIOLOGY PACS ARE DESIGNED TO STORE, RETRIEVE, TRANSMIT AND DISPLAY DIGITAL IMAGES GENERATED DURING CARDIAC PROCEDURES SUCH AS ECHOCARDIOGRAPHY, STRESS TESTING, CATHETERIZATION AND CARDIAC NUCLEAR MEDICINE.

  • Immunology
  • Patient Monitoring
  • Targeted Therapy
  • Vaccine
  • Market Size
  • CAREDX ENTERS INTO LICENSING AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA

CARDIOLOGY PACS ARE DESIGNED TO STORE, RETRIEVE, TRANSMIT AND DISPLAY DIGITAL IMAGES GENERATED DURING CARDIAC PROCEDURES SUCH AS ECHOCARDIOGRAPHY, STRESS TESTING, CATHETERIZATION AND CARDIAC NUCLEAR MEDICINE.

  • Immunology
  • Patient Monitoring
  • Vaccine
  • East Asia
  • South Korea

Patients will be randomized in a ##:##:## fashion to placebo or one of two different doses of AG## on a background of stable heart failure therapy.

  • Endocrine Disease
  • Immunology
  • Targeted Therapy
  • Vaccine
  • Alnylam Pharmaceuticals, Inc.

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Drug Development
  • Immunology
  • Targeted Therapy
  • Vaccine
  • Novartis AG
  • SOUL MATE - PACEMAKER - PRODUCT DESCRIPTION

One unit refers to one cardiac resynchronization therapy - pacemaker.

  • Immunology
  • Orthopedics
  • Patient Monitoring
  • Vaccine
  • United States

The prominent features of this report are - ##.

  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World
  • Conatus Pharmaceuticals Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Medical Biotechnology
  • Monoclonal Antibody
  • Targeted Therapy
  • Vaccine
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Immunology
  • Targeted Therapy
  • Therapy
  • Vaccine
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Immunology
  • Immunotherapy
  • Targeted Therapy
  • Vaccine
  • Apexigen, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Immunology
  • Neurological Disorder
  • Targeted Therapy
  • Therapy
  • Vaccine
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Immunology
  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Vaccine
  • Target
  • 5. All the trials included are unique trials.

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Clinical Trial
  • Immunology
  • Targeted Therapy
  • Transplantation
  • Vaccine

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor

  • Monoclonal Antibody
  • Orthopedics
  • Targeted Therapy
  • Vaccine
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Immunology
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Vaccine
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunology
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Vaccine

Hoffmann-La Roche Ltd ## ## ## ## ## ## Clinical Research and Biosciences India Private Limited (Inactive) ## ## ## ## ## ## ClinAssess GmbH ## ## ## ## ## ## Bavarian Nordic A/ S ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## APT

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative